On Tuesday, Inari Medical Inc. (NASDAQ:NARI) received a reaffirmed Buy rating and an $86.00 price target from BTIG following the company's release of its third-quarter financial results. Inari Medical reported a third-quarter revenue of $153.4 million, marking a 21.4% increase year-over-year and a 5% rise sequentially, surpassing the consensus estimate of $150.7 million.
The company had previously indicated a third-quarter sales forecast of approximately $150 million, making this a roughly $3 million outperformance against expectations, attributed to growth in U.S. VTE and International sales.
The company has raised its full-year revenue outlook by $3.5 million at the midpoint, now expecting between $601.5 million and $604.5 million, representing a 21.9-22.5% year-over-year increase. This adjustment comes after the previous range was set between $594.5 million and $604.5 million.
The reported quarter also saw an improvement in the operating loss, which narrowed to $13.6 million. Gross margins showed a slight quarter-over-quarter increase, reaching 87.1%.
Inari Medical has reiterated its goal to achieve sustained operating profitability in the first half of 2025. The company's performance this quarter underscores robust underlying procedure volumes in the U.S. market, with no indication of a slowdown or significant shift in market dynamics.
The anticipation is high for the PEERLESS Randomized Controlled Trial (RCT) results, which are to be presented on Wednesday at the Transcatheter Cardiovascular Therapeutics (TCT) meeting.
Management's commentary has been optimistic regarding the potential for mechanical thrombectomy to continue gaining market share from catheter-directed thrombolytics (CDT). With a roughly $10,000 average selling price, the remaining market share of CDT represents an approximate $150 million opportunity.
BTIG expects NARI shares to experience an uptick on the back of these strong third-quarter results and the forthcoming PEERLESS data readout.
Inari Medical's strategy includes maintaining core growth in the U.S. VTE segment, expanding into new geographic markets, and introducing new products aimed at long-term growth, while also focusing on improving profitability metrics. The maintained $86 price target is based on a projected 6.5x multiple on the firm's 12-24 month sales estimate.
In other recent news, Inari Medical has seen a flurry of activity from analyst firms. Baird increased the stock price target for Inari Medical to $66, maintaining an Outperform rating. The firm anticipates a strong third-quarter performance from Inari Medical, potentially leading to a significant increase in the stock's valuation.
Meanwhile, Needham maintained a Hold rating on the company, awaiting results from the PEERLESS study comparing Inari's FlowTriever system to traditional treatments for pulmonary embolism.
Stifel initiated coverage on Inari Medical with a Hold rating, citing potential market growth against competitive and regulatory challenges. Deutsche Bank reiterated a Buy rating, expressing confidence in Inari Medical's growth potential despite recent safety concerns. Piper Sandler reaffirmed a Neutral rating, following a recent animal study investigating the company's FlowSaver technology.
Inari Medical recently released its second-quarter earnings report, highlighting a modest revenue beat and a raised forecast, reflecting a 17% growth in its core US Venous Thromboembolism business. However, the operational loss was larger than expected.
On the management front, Kevin Strange is set to replace Mitch Hill in an unexpected Chief Financial Officer transition. These are the recent developments for Inari Medical.
InvestingPro Insights
Inari Medical's recent financial performance aligns with several key metrics and insights from InvestingPro. The company's impressive gross profit margin of 87.15% for the last twelve months as of Q2 2024 reflects its strong pricing power and efficient cost management, which is consistent with the reported 87.1% gross margin in the latest quarter. This high margin is particularly noteworthy given Inari's focus on improving profitability metrics.
However, investors should be aware that Inari Medical is currently not profitable, with a negative operating income of $20.56 million over the last twelve months. This aligns with the company's stated goal to achieve sustained operating profitability in the first half of 2025, as mentioned in the article.
An InvestingPro Tip highlights that Inari operates with a moderate level of debt, which could provide financial flexibility as the company pursues its growth strategies in U.S. VTE and international markets. Additionally, the company's strong revenue growth of 24.67% over the last twelve months supports the positive outlook and raised revenue guidance mentioned in the article.
For investors seeking a more comprehensive analysis, InvestingPro offers 7 additional tips for Inari Medical, providing a deeper understanding of the company's financial position and market performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.